These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 17118125

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M, Brazilian Pegasys Cooperative Study Group.
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [Abstract] [Full Text] [Related]

  • 3. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G.
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [Abstract] [Full Text] [Related]

  • 4. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [Abstract] [Full Text] [Related]

  • 5. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F.
    Ann Hepatol; 2012 Feb; 11(1):52-61. PubMed ID: 22166561
    [Abstract] [Full Text] [Related]

  • 6. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA, PROGRESS Study Investigators.
    Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O.
    Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
    Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B.
    Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
    [Abstract] [Full Text] [Related]

  • 10. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, Koh KC, Yoo BC, Rhee JC, Song SM.
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
    Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Teuber G, Wollschlaeger S, Baumgarten A, Simon KG, Moog G, Dikopoulos N, Mauss S.
    J Viral Hepat; 2010 Jul; 17(7):459-68. PubMed ID: 20158603
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS.
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [Abstract] [Full Text] [Related]

  • 16. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR.
    J Hepatol; 2005 Sep; 43(3):425-33. PubMed ID: 15990196
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A, Austrian Hepatitis Study Group.
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.